Middle East & Africa Biopharmaceuticals Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
The Middle East & Africa biopharmaceuticals market was valued at US$ 13.36 billion in 2022 and is projected to reach US$ 28.81 billion by 2028. It is estimated to register a CAGR of 13.7% from 2022 to 2028.
Accelerated Clinical Trials to Offer Lucrative Opportunities to Middle East & Africa Biopharmaceuticals Market
Accelerated progress of clinical trials will ultimately result in the development and commercialization of new drugs targeting rare as well as commonly inherited diseases. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive, acute leukemia that has been historically difficult to diagnose. In December 2018, Tagraxofusp became the first therapy approved for treating BPDCN, which then became the standard care method. During clinical trials, more than 90% of patients who never received any treatment responded to therapy. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that weakens muscles, impacts physical function, and causes irreversible brain and spinal cord damage. To date, only 2 products are approved for slowing the functional decline associated with ALS. The accelerated clinical trials for developing new products targeting ALS are in progress. For example, antisense oligonucleotides (ASOs) have been showing promising results in clinical trials involving patients suffering from ALS. Further, different gene therapy approaches, targeting multiple mutations in patients for both sporadic ALS and familial ALS, are in clinical trials. Thus, clinical trials of an extensive pipeline of biopharmaceuticals are expected to offer lucrative growth opportunities to the Middle East & Africa biopharmaceuticals market in the coming years.
Middle East & Africa Biopharmaceuticals Market Overview
The Middle East & Africa biopharmaceuticals market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. Saudi Arabia is expected to account for the largest market share and is expected to develop moderately in the Middle East & Africa during the forecast period. This is mainly due to Saudi Arabia's Ministry signing MOM or agreement with biotech companies to establish a production facility in the country. For example, Saudi Arabia's Ministry of Investment (MISA) and clinical-stage AI-driven drug discovery company Insilico Medicine announced signing a memorandum of understanding (MOU) to support the development of the AI-driven biotech industry in the KSA. Additionally, Merck KGaA announced a signing agreement with SaudiVax of Saudi Arabia to design and construct a multimodality biologic manufacturing facility to promote localized production infrastructure in the Middle East & Africa.
Saudi Arabia is the most significant pharmaceutical market in the Middle East due to increasing gross domestic product (GDP) and is ranked in the top 30 worldwide. It is an encouraging market for biopharmaceuticals firms. For instance, Aurobindo started investing in Saudi Arabia by producing medicines to treat chronic diseases such as diabetes, heart disease, and hypertension. Likewise, many top biopharmaceuticals firms are planning to set up a production base in the UAE. For example, AstraZeneca announced the expansion of its partnership with AI-based company G42 Healthcare by signing an agreement to manufacture innovative drugs in Abu Dhabi. The agreement focuses on collaboration in four key areas—localizing innovative industries, R&D, innovation, and sustainability—to promote the UAE as a hub for future industries.
Middle East & Africa Biopharmaceuticals Market Revenue and Forecast to 2028 (US$ Billion)
Middle East & Africa Biopharmaceuticals Market Segmentation
The Middle East & Africa biopharmaceuticals market is segmented into product type, application, and country.
Based on product type, the Middle East & Africa biopharmaceuticals market is segmented into monoclonal antibodies, recombinant vaccines, conventional vaccines, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell & gene therapies, cytokines/interferon/interleukins, and others. In 2022, the monoclonal antibodies segment held the largest share of the Middle East & Africa biopharmaceuticals market.
The recombinant vaccines segment is further segmented into cancer vaccine, malaria vaccine, ebola vaccine, hepatitis-B vaccine, tetanus vaccine, diphtheria vaccine, cholera vaccine, and others. The conventional vaccines segment is further segmented into polio vaccine, pox vaccine, and others. The recombinant growth factors segment is further segmented into erythropoietin and granulocyte colony stimulating factor. The purified proteins segment is further segmented into leukemia inhibitory factor (LIF), P53 protein, P38 protein, and others. The recombinant proteins segment is further segmented into serum albumin, amyloid protein, defensin, and transferrin. The recombinant hormones segment is further segmented into recombinant human growth hormones, recombinant insulin, and other recombinant hormones. The recombinant enzymes segment is further segmented into enterokinase, cyclase, caspase, and cathepsin. The cell & gene therapies segment is further segmented into allogenic products, autologous products, and acellular products.
Based on application, the Middle East & Africa biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. In 2022, the oncology segment held the largest share of the Middle East & Africa biopharmaceuticals market.
Based on country, the Middle East & Africa biopharmaceuticals market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. In 2022, Saudi Arabia held the largest share of the Middle East & Africa biopharmaceuticals market.
AbbVie Inc, AGC Biologics AS, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Eli Lilly and Co, Johnson & Johnson, Lonza Group AG, and Thermo Fisher Scientific Inc are among the leading companies operating in the Middle East & Africa biopharmaceuticals market.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Middle East & Africa Biopharmaceuticals Market – by Product Type
1.3.2 Middle East & Africa Biopharmaceuticals Market – by Application
1.3.3 Middle East & Africa Biopharmaceuticals Market – by Country
2. Middle East & Africa Biopharmaceuticals Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Biopharmaceuticals Market – Market Landscape
4.1 Overview
4.2 Middle East & Africa PEST Analysis
4.3 Expert’s Opinion
5. Middle East & Africa Biopharmaceuticals Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Application in Cancer Therapeutics
5.1.2 Potential to Treat Rare Diseases
5.2 Market Restraints
5.2.1 High Cost of Manufacturing Infrastructure
5.3 Market Opportunities
5.3.1 Accelerated Clinical Trials
5.4 Future Trends
5.4.1 Contract Manufacturing of Biopharmaceuticals
5.5 Impact Analysis
6. Biopharmaceuticals Market – Middle East & Africa Analysis
6.1 Middle East & Africa Biopharmaceuticals Market Revenue Forecast and Analysis
7. Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 – by Product Type
7.1 Overview
7.2 Middle East & Africa Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
7.3 Monoclonal Antibodies
7.3.1 Overview
7.3.2 Monoclonal Antibodies: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Recombinant Vaccines
7.4.1 Overview
7.4.2 Recombinant Vaccines: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Cancer Vaccine
7.4.2.1.1 Overview
7.4.2.1.2 Cancer Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Malaria Vaccine
7.4.2.2.1 Overview
7.4.2.2.2 Malaria Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.3 Ebola Vaccine
7.4.2.3.1 Overview
7.4.2.3.2 Ebola Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.4 Hepatitis-B Vaccine
7.4.2.4.1 Overview
7.4.2.4.2 Hepatitis-B Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.5 Tetanus Vaccine
7.4.2.5.1 Overview
7.4.2.5.2 Tetanus Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.6 Diphtheria Vaccine
7.4.2.6.1 Overview
7.4.2.6.2 Diphtheria Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.7 Cholera Vaccine
7.4.2.7.1 Overview
7.4.2.7.2 Cholera Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.8 Others
7.4.2.8.1 Overview
7.4.2.8.2 Others: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Conventional Vaccines
7.5.1 Overview
7.5.2 Conventional Vaccines: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Polio Vaccine
7.5.2.1.1 Overview
7.5.2.1.2 Polio Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Pox Vaccine
7.5.2.2.1 Overview
7.5.2.2.2 Pox Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Other Conventional Vaccine
7.5.2.3.1 Overview
7.5.2.3.2 Other Conventional Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Recombinant Growth Factors
7.6.1 Overview
7.6.2 Recombinant Growth Factors: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.1 Erythropoietin
7.6.2.1.1 Overview
7.6.2.1.2 Erythropoietin: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.2 Granulocyte Colony Stimulating Factor
7.6.2.2.1 Overview
7.6.2.2.2 Granulocyte Colony Stimulating Factor: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Purified Proteins
7.7.1 Overview
7.7.2 Purified Proteins: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.1 Leukemia Inhibitory Factor (LIF)
7.7.2.1.1 Overview
7.7.2.1.2 Leukemia Inhibitory Factor (LIF): Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.2 P53 Protein
7.7.2.2.1 Overview
7.7.2.2.2 P53 Protein: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.3 P38 Protein
7.7.2.3.1 Overview
7.7.2.3.2 P38 Protein: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.4 Other Purified Proteins
7.7.2.4.1 Overview
7.7.2.4.2 Other Purified Proteins: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8 Recombinant Proteins
7.8.1 Overview
7.8.2 Recombinant Proteins: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8.2.1 Serum Albumin
7.8.2.1.1 Overview
7.8.2.1.2 Serum Albumin: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8.2.2 Amyloid Protein
7.8.2.2.1 Overview
7.8.2.2.2 Amyloid Protein: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8.2.3 Defensin
7.8.2.3.1 Overview
7.8.2.3.2 Defensin: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8.2.4 Transferrin
7.8.2.4.1 Overview
7.8.2.4.2 Transferrin: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.9 Recombinant Hormones
7.9.1 Overview
7.9.2 Recombinant Hormones: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.9.2.1 Recombinant Human Growth Hormones
7.9.2.1.1 Overview
7.9.2.1.2 Recombinant Human Growth Hormones: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.9.2.2 Recombinant Insulin
7.9.2.2.1 Overview
7.9.2.2.2 Recombinant Insulin: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.9.2.3 Other Recombinant Hormones
7.9.2.3.1 Overview
7.9.2.3.2 Other Recombinant Hormones: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10 Recombinant Enzymes
7.10.1 Overview
7.10.2 Recombinant Enzymes: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10.2.1 Enterokinase
7.10.2.1.1 Overview
7.10.2.1.2 Enterokinase: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10.2.2 Cyclase
7.10.2.2.1 Overview
7.10.2.2.2 Cyclase: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10.2.3 Caspase
7.10.2.3.1 Overview
7.10.2.3.2 Caspase: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10.2.4 Cathepsin
7.10.2.4.1 Overview
7.10.2.4.2 Cathepsin: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.11 Cell and Gene Therapies
7.11.1 Overview
7.11.2 Cell and Gene Therapies: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.11.2.1 Allogenic Products
7.11.2.1.1 Overview
7.11.2.1.2 Allogenic Products: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.11.2.2 Autologous Products
7.11.2.2.1 Overview
7.11.2.2.2 Autologous Products: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.11.2.3 Acellular Products
7.11.2.3.1 Overview
7.11.2.3.2 Acellular Products: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.12 Cytokines/Interferon/Interleukins
7.12.1 Overview
7.12.2 Cytokines/Interferon/Interleukins: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.13 Others (mRNA Based Therapeutics, etc.)
7.13.1 Overview
7.13.2 Others (mRNA Based Therapeutics, etc.): Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8. Middle East & Africa Biopharmaceuticals Market Analysis and Forecasts to 2028 – by Application
8.1 Overview
8.2 Middle East & Africa Biopharmaceuticals Market, by Application 2021 & 2028 (%)
8.3 Oncology
8.3.1 Overview
8.3.2 Oncology: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Inflammatory and Infectious Diseases
8.4.1 Overview
8.4.2 Inflammatory and Infectious Diseases: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Autoimmune Disorders
8.5.1 Overview
8.5.2 Autoimmune Disorders: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Metabolic Disorders
8.6.1 Overview
8.6.2 Metabolic Disorders: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Hormonal Disorders and Growth Failure
8.7.1 Overview
8.7.2 Hormonal Disorders and Growth Failure: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.8 Cardiovascular Diseases
8.8.1 Overview
8.8.2 Cardiovascular Diseases: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.9 Neurological Diseases
8.9.1 Overview
8.9.2 Neurological Diseases: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.10 Other Therapeutic Applications
8.10.1 Overview
8.10.2 Other Therapeutic Applications: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9. Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 – Country Analysis
9.1 Overview
9.1.1 Overview
9.1.2 Middle East & Africa: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
9.1.2.1 UAE: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.1.2.1.1 UAE: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.1.2.1.1.1 UAE: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.1.2.1.1.2 UAE: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.1.2.1.1.3 UAE: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.1.2.1.1.4 UAE: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.1.2.1.1.5 UAE: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.1.2.1.1.6 UAE: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.1.2.1.1.7 UAE: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.1.2.1.1.8 UAE: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.1.2.1.2 UAE: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.1.2.2 Saudi Arabia: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.1.2.2.1 Saudi Arabia: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.1.2.2.1.1 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.1.2.2.1.2 Saudi Arabia: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.1.2.2.1.3 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.1.2.2.1.4 Saudi Arabia: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.1.2.2.1.5 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.1.2.2.1.6 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.1.2.2.1.7 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.1.2.2.1.8 Saudi Arabia: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.1.2.2.2 Saudi Arabia: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.1.2.3 South Africa: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.1.2.3.1 South Africa: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.1.2.3.1.1 South Africa: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.1.2.3.1.2 South Africa: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.1.2.3.1.3 South Africa: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.1.2.3.1.4 South Africa: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.1.2.3.1.5 South Africa: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.1.2.3.1.6 South Africa: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.1.2.3.1.7 South Africa: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.1.2.3.1.8 South Africa: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.1.2.3.2 South Africa: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.1.2.4 Rest of Middle East & Africa: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.1.2.4.1 Rest of Middle East & Africa: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.1.2.4.1.1 Rest of Middle East & Africa: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.1.2.4.1.2 Rest of Middle East & Africa: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.1.2.4.1.3 Rest of Middle East & Africa: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.1.2.4.1.4 Rest of Middle East & Africa: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.1.2.4.1.5 Rest of Middle East & Africa: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.1.2.4.1.6 Rest of Middle East & Africa: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.1.2.4.1.7 Rest of Middle East & Africa: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.1.2.4.1.8 Rest of Middle East & Africa: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.1.2.4.2 Rest of Middle East & Africa: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
10. Middle East & Africa Biopharmaceuticals Market – Industry Landscape
10.1 Overview
10.2 Organic Growth Strategies
10.2.1 Overview
10.3 Inorganic Growth Strategies
10.3.1 Overview
11. Company Profiles
11.1 Amgen Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 AbbVie Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Eli Lilly and Co
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Bristol-Myers Squibb Co
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Johnson & Johnson
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Boehringer Ingelheim International GmbH
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Thermo Fisher Scientific Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 AGC Biologics AS
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Lonza Group AG
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
LIST OF TABLES
Table 1. Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Table 2. UAE Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. UAE Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 4. UAE Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 5. UAE Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 6. UAE Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 7. UAE Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 8. UAE Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 9. UAE Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 10. UAE Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 11. UAE Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 12. Saudi Arabia Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 13. Saudi Arabia Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 14. Saudi Arabia Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 15. Saudi Arabia Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 16. Saudi Arabia Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 17. Saudi Arabia Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 18. Saudi Arabia Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 19. Saudi Arabia Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 20. Saudi Arabia Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 21. Saudi Arabia Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 22. South Africa Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 23. South Africa Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 24. South Africa Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 25. South Africa Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 26. South Africa Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 27. South Africa Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 28. South Africa Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 29. South Africa Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 30. South Africa Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 31. South Africa Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 32. Rest of Middle East & Africa Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 33. Rest of Middle East & Africa Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 34. Rest of Middle East & Africa Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)
Table 35. Rest of Middle East & Africa Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)
Table 36. Rest of Middle East & Africa Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 37. Rest of Middle East & Africa Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)
Table 38. Rest of Middle East & Africa Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)
Table 39. Rest of Middle East & Africa Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)
Table 40. Rest of Middle East & Africa Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)
Table 41. Rest of Middle East & Africa Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 42. Recent Organic Growth Strategies in Biopharmaceuticals Market
Table 43. Recent Inorganic Growth Strategies in the Middle East & Africa biopharmaceuticals market
Table 44. Glossary of Terms
LIST OF FIGURES
Figure 1. Middle East & Africa Biopharmaceuticals Market Segmentation
Figure 2. Middle East & Africa Biopharmaceuticals Market, by Country
Figure 3. Middle East & Africa Biopharmaceuticals Market Overview
Figure 4. Monoclonal Antibodies Segment Held Largest Share of Product Type Segment in Middle East & Africa Biopharmaceuticals Market
Figure 5. Saudi Arabia Expected to Show Remarkable Growth During Forecast Period
Figure 6. Middle East & Africa: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. Middle East & Africa Biopharmaceuticals Market: Impact Analysis of Drivers and Restraints
Figure 9. Middle East & Africa Biopharmaceuticals Market – Revenue Forecast and Analysis – 2020–2028
Figure 10. Middle East & Africa Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
Figure 11. Monoclonal Antibodies: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Recombinant Vaccines: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Cancer Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Malaria Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Ebola Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Hepatitis-B Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Tetanus Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Diphtheria Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Cholera Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Others: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Conventional Vaccines: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Polio Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Pox Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Other Conventional Vaccine: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Recombinant Growth Factors: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Erythropoietin: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Granulocyte Colony Stimulating Factor: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Purified Proteins: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Leukemia Inhibitory Factor (LIF): Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. P53 Protein: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. P38 Protein: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Other Purified Proteins: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Recombinant Proteins: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Serum Albumin: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Amyloid Protein: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Defensin: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. Transferrin: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. Recombinant Hormones: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. Recombinant Human Growth Hormones: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Recombinant Insulin: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. Other Recombinant Hormones: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 42. Recombinant Enzymes: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 43. Enterokinase: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 44. Cyclase: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 45. Caspase: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 46. Cathepsin: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 47. Cell and Gene Therapies: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 48. Allogenic Products: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 49. Autologous Products: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 50. Acellular Products: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 51. Cytokines/Interferon/Interleukins: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 52. Others (mRNA Based Therapeutics, etc.): Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 53. Middle East & Africa Biopharmaceuticals Market, by Application 2021 & 2028 (%)
Figure 54. Oncology: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 55. Inflammatory and Infectious Diseases: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 56. Autoimmune Disorders: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 57. Metabolic Disorders: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 58. Hormonal Disorders and Growth Failure: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 59. Cardiovascular Diseases: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 60. Neurological Diseases: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 61. Other Therapeutic Applications: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 62. Middle East & Africa: Biopharmaceuticals Market, by Key Country – Revenue (2021) (US$ Million)
Figure 63. UAE: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 64. Saudi Arabia: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 65. South Africa: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 66. Rest of Middle East & Africa: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
- AbbVie Inc
- AGC Biologics AS
- Amgen Inc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Eli Lilly and Co
- Johnson & Johnson
- Lonza Group AG
- Thermo Fisher Scientific Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa biopharmaceutical market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa biopharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the biopharmaceutical market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution